CHO Pharma, Inc.

TPEX:6586 Stock Report

Market Cap: NT$11.0b

CHO Pharma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chung-Yi Wu

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure2.8yrs
CEO ownership2.8%
Management average tenureno data
Board average tenure3.6yrs

Recent management updates

Recent updates

Here's Why We're Not Too Worried About CHO Pharma's (GTSM:6586) Cash Burn Situation

Mar 24
Here's Why We're Not Too Worried About CHO Pharma's (GTSM:6586) Cash Burn Situation

We're Not Very Worried About CHO Pharma's (GTSM:6586) Cash Burn Rate

Dec 09
We're Not Very Worried About CHO Pharma's (GTSM:6586) Cash Burn Rate

CEO

Chung-Yi Wu

2.8yrs

Tenure

Dr. Chung-Yi Wu serves as President at CHO Pharma, Inc. since March 2022 and serves as its General Manager & Director since 2022 and also serves as its Chief Executive Officer. He served as Executive Vice...

Board Members

NamePositionTenureCompensationOwnership
Chung-Yi Wu
President3yrsno data2.84%
NT$ 311.3m
Ming-Hsing Tsai
Director3yrsno data8.38%
NT$ 918.1m
Pan-Chyr Yang
Member of Scientific Advisory Boardno datano datano data
Chi-Huey Wong
Chairman of Scientific Advisory Boardno datano datano data
Shaw T. Chen
Member of Scientific Advisory Boardno datano datano data
Hsieng S. Lu
Member of Scientific Advisory Boardno datano datano data
Chao-Long Chen
Chairmanno datano datano data
Shuan-Ta Liu
Independent Director5.6yrsno datano data
Kuo-I Lin
Member of Scientific Advisory Board3.6yrsno datano data
Che Alex Ma
Member of Scientific Advisory Boardno datano datano data
Mei-Shang Ho
Member of Scientific Advisory Board4yrsno datano data
Chung-Liang Chien
Independent Directorno datano datano data

3.6yrs

Average Tenure

Experienced Board: 6586's board of directors are considered experienced (3.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 04:57
End of Day Share Price 2025/01/02 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CHO Pharma, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution